Evoked otoacoustic emissions and pure tone threshold audiometry in patients receiving cisplatinum therapy.

Eight children and young adults with cancer were evaluated serially using pure tone audiometry as well as registration of click-evoked otoacoustic emissions (EOAE) 1 day prior to therapy as well as after various numbers of doses of cisplatinum. A reduction of EOAE-amplitudes following cisplatinum therapy was observed in all patients. This reduction tended to recover after the end of cisplatinum administration. Since EOAE are believed to result from cochlear bio-mechanical processes, the reduced emissions are interpreted as signs of cochlear dysfunction. We conclude, that EOAE testing may be a simple, non-invasive method that may detect early, transient functional impairment of hearing due to ototoxic agents such as cisplatinum, even in children. Further controlled trials are needed.

[1]  P. Merriam,et al.  Cis-dichlorodiammineplatinum (II) (NSC-119875): hearing loss and other toxic effects in rhesus monkeys. , 1975, Cancer chemotherapy reports.

[2]  Evoked acoustic emission: clinical application. , 1985, Acta oto-laryngologica. Supplementum.

[3]  J. H. Ryu,et al.  Cis-Diamminedichloroplatinum (II) Ototoxicity in the Guinea Pig , 1981, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[4]  M. Anniko,et al.  Cisplatin: evaluation of its ototoxic potential. , 1986, American journal of otolaryngology.

[5]  C. Merrin.  Treatment of advanced bladder cancer with cis-diamminedichloroplatinum (II NSC 119875): a pilot study. , 1978, The Journal of urology.

[6]  Jochen Schacht,et al.  Evidence that phosphoinositides mediate motility in cochlear outer hair cells , 1987, Hearing Research.

[7]  Evoked oto-acoustic emissions from adults and infants: clinical applications. , 1988, Acta oto-laryngologica.

[8]  C. G. Wright,et al.  Inner ear histopathology in patients treated with Cis‐Platinum. , 1982, The Laryngoscope.

[9]  G. Laurell,et al.  The ototoxic effect of cisplatin on guinea pigs in relation to dosage , 1989, Hearing Research.

[10]  P Bray,et al.  An advanced cochlear echo technique suitable for infant screening. , 1987, British journal of audiology.

[11]  Y. Nakai,et al.  Ototoxicity of the Anticancer Drug Cisplatin , 1981 .

[12]  C. G. Wright,et al.  Ototoxicity of low‐ and moderate‐dose cisplatin , 1985, Cancer.

[13]  P. Bonfils,et al.  Evoked otoacoustic emissions in newborn hearing screening , 1990, The Laryngoscope.

[14]  E. Cvitkovic,et al.  cis-Platinum ototoxicity. , 1978, Clinical toxicology.

[15]  Y. Nakai,et al.  Ototoxicity of the anticancer drug cisplatin. An experimental study. , 1982, Acta oto-laryngologica.

[16]  D. Kemp.  Stimulated acoustic emissions from within the human auditory system. , 1978, The Journal of the Acoustical Society of America.

[17]  M. F. Ethier,et al.  Ototoxicity of cis-dichlorodiammine platinum (II) in the guinea pig. , 1975, Toxicology and applied pharmacology.

[18]  J. M. Grant,et al.  Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. , 1982, Cancer treatment reports.

[19]  I. Niroomand-Rad,et al.  Effect of cisplatin on the plasma membrane phosphatase activities in ascites sarcoma-180 cells: a cytochemical study. , 1983, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[20]  J. Towfighi,et al.  Cis‐platinum Ototoxicity: Clinical experience and temporal bone histopathology , 1983, The Laryngoscope.

[21]  Evoked acoustic emissions in high-frequency vs. low/medium-frequency hearing loss. , 1989, Scandinavian audiology.

[22]  D. Lim.  Cochlear micromechanics in understanding otoacoustic emission. , 1986, Scandinavian audiology. Supplementum.